Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24253514 | 0.84 | LMNA (0.44) | ALDH1A1CA1CA2GABRA1GABRB1 | |
| SCHEMBL4546363 | 0.76 | GABRA1 (0.35) | CA1CA2GABRA1GABRB1GABRB2 | |
| SCHEMBL19545353 | 0.75 | GLP1R (0.32) | ALDH1A1 | |
| SCHEMBL17947684 | 0.75 | — | — | |
| SCHEMBL12778210 | 0.74 | PRKCZ (0.44) | — | |
| SCHEMBL22045619 | 0.71 | ALDH1A1 (0.53) | ALDH1A1 | |
| SCHEMBL371433 | 0.71 | CA1 (0.47) | CA1CA2GABRA1GABRB1GABRB2 | |
| SCHEMBL12702792 | 0.70 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL2230006 | 0.70 | UGT2B7 (0.42) | ALDH1A1TRPA1LMNA | |
| SCHEMBL24481271 | 0.69 | ESR1 (0.36) | CA1CA2GABRA1GABRB1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9737516-B2 | Bicyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160213654-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2016-07-28 | — | — | US | disclosed |
| US-9315501-B2 | Bicyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150148375-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148375-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | ALDH1A1 4585/4885CA1 4845/4885CA2 4746/4885 |
| US-20160213654-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | ALDH1A1 4585/4885CA1 4845/4885CA2 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.